Similar to CML, in BCR::ABL1-negative MPN, progression to AP is defined by the presence of 10 to 19% of peripheral blood or bone marrow blasts, while BP is defined by the presence of 20% or more blasts. The gene discussed is BCR; the disease is myeloproliferative disorder.